ArticleNanomedicine (London, England)2024
Co-delivery of temozolomide and quercetin with folic acid-conjugated exosomes in glioblastoma treatment.
Article in Nanomedicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Extracellular Vesicles as a Potential Tool in Cancer Diagnosis and Therapy.Biomedicines · 2026Review
- Cryogenic Electron Microscopy of Extracellular Vesicles from Temozolomide-Treated Glioblastoma Cells Reveals Great Morphological Heterogeneity.Nanomaterials (Basel, Switzerland) · 2026Article
- Quercetin Affects Carcinogenic Phenotype of Breast and Lung Cancer Cells Differentially Through Sterol Regulation Mediated by MALAT1 Perturbation.Chemistry, an Asian journal · 2026Article
- Folic Acid-Guided PLGA-Zein Core-Shell Nanoparticles for Co-Delivery of Temozolomide and Ellagic Acid to Overcome PARP-Mediated Chemoresistance in Glioblastoma.Pharmaceutics · 2026Article
- Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges.Molecular biology reports · 2026Review
- Controlling Biogenesis and Engineering of Exosomes to Inhibit Growth and Promote Death in Glioblastoma Multiforme.Brain sciences · 2026Review
- Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma.International journal of nanomedicine · 2026Article
- CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation.Cancer management and research · 2026Review
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- A Validated UPLC-MS/MS Method for Monitoring Temozolomide and Perillyl Alcohol Metabolites in Biological Matrices: Insights From a Preclinical Pharmacokinetic Study.Biomedical chromatography : BMC · 2025Article
- Oxidative Stress and Antioxidants in Glioblastoma: Mechanisms of Action, Therapeutic Effects and Future Directions.Antioxidants (Basel, Switzerland) · 2025Review
- Liposomes and Extracellular Vesicles as Distinct Paths Toward Precision Glioma Treatment.International journal of molecular sciences · 2025Review
- Brain Endothelial Cells in Blood-Brain Barrier Regulation and Neurological Therapy.International journal of molecular sciences · 2025Review
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability.Journal of nanobiotechnology · 2025Review
- Exosome technology: A novel and effective drug delivery system in the field of cancer therapy.World journal of gastrointestinal oncology · 2025Article
- The Role of Exosomes as a Key Factor of Cytostatic Resistance in Cancer: Mechanisms of Action, Potential Biomarkers, and Possible Exosome-Based Therapies.Oncology research · 2025Review
- Advancing through the blood-brain barrier: mechanisms, challenges and drug delivery strategies.ADMET & DMPK · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.